@phdthesis{Flegler2012,
  author    = {Flegler, Katharina},
  title     = {Untersuchung der Expression von Knochensialoprotein (BSP) an Gewebe von Knochenmetastasen mittels Immunhistologie : Vergleich eines Antik{\"o}rpers gegen nicht-glykosyliertes BSP mit einem Antik{\"o}rper gegen glykosyliertes BSP},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-71642},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2012},
  abstract  = {Knochensialoprotein (BSP) ist ein Protein der extrazellul{\"a}ren Matrix im Knochen und mineralisierten Geweben, wird aber auch von verschiedenen Tumorzellen exprimiert (Bellahcene et al., 1994, 1997, 1998). Dies ist assoziiert mit einer schlechten Prognose und einem erh{\"o}hten Risiko f{\"u}r eine sp{\"a}tere Entwicklung von Knochenmetastasen. Diel et al. (1999) konnte zeigen, dass ein erh{\"o}hter Serum-BSP-Wert bei Patientinnen mit Mammakarzinom zu einem geh{\"a}uften Auftreten von Knochenmetastasen im Laufe der Erkrankung f{\"u}hrt. BSP scheint ein Marker f{\"u}r die Entstehung von Knochenmetastasen zu sein. In der Literatur ist ein Antik{\"o}rper beschrieben, der ein Epitop des BSP erkennt, welches im BSP aus Tumorzellen nicht glykosyliert ist, im BSP aus mineralisiertem Gewebe allerdings schon (Armbruster et al., 2009). Im Tiermodell konnte gezeigt werden, dass Knochenmetastasen verhindert werden k{\"o}nnen bei gleichzeitiger Gabe von Tumorzellen und Antik{\"o}rpern gegen BSP beziehungsweise, dass bei vorhandenen Knochenmetastasen eine Behandlung der Tiere mit einem Anti-BSP-Antik{\"o}rper die Metastasen zur{\"u}ckbildet (B{\"a}uerle et al., 2005, 2006). In der aktuellen Arbeit wird die Expression von BSP an menschlichem Gewebe von Knochenmetastasen mit unterschiedlichen Prim{\"a}rtumoren mittels Immunhistochemie untersucht. Insgesamt wurden 35 F{\"a}lle von Knochenmetastasen mit Prim{\"a}rtumor eines Mammakarzinoms untersucht, wobei 22,9\% eine BSP Expression aufweisen, davon 5,7\% eine starke. Knochenmetastasen mit dem Prim{\"a}rtumor Prostatakarzinom sind mit 8 F{\"a}llen repr{\"a}sentiert, wobei 75\% positiv f{\"u}r BSP sind, davon 25\% stark positiv. Die einzelnen F{\"a}lle zeigen eine starke BSP Expression im Stroma und eine schwache BSP Expression der Tumorzellen. Diese Ergebnisse des Antik{\"o}rpers gegen normal glykosyliertes BSP wurden verglichen mit dem Antik{\"o}rper gegen nicht glykosyliertes BSP. Der Nachweis von BSP in Tumorzellen zeigt dasselbe Ergebnis, BSP im Stroma wird durch den Antik{\"o}rper gegen nicht- glykosyliertes BSP intensiver dargestellt. Daraus l{\"a}sst sich folgern, dass der Antik{\"o}rper gegen nicht- glykosyliertes BSP nicht spezifisch f{\"u}r die Isoform des BSP aus Tumorzellen ist, sondern gleichermaßen in der Routinediagnostik von BSP eingesetzt werden kann. Die Untersuchung k{\"o}nnte sogar darauf hinweisen, dass dieser Antik{\"o}rper die nicht- glykosylierte Isoform im Stroma erkennt und damit bei Untersuchung des Stromas die bessere Alternative darstellt.},
  subject      = {Knochensialoprotein},
  language  = {de}
}
@article{HaddadChenCarlinetal.2012,
  author    = {Haddad, Dana and Chen, Chun-Hao and Carlin, Sean and Silberhumer, Gerd and Chen, Nanhai G. and Zhang, Qian and Longo, Valerie and Carpenter, Susanne G. and Mittra, Arjun and Carson, Joshua and Au, Joyce and Gonen, Mithat and Zanzonico, Pat B. and Szalay, Aladar A. and Fong, Yuman},
  title     = {Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter},
  series = {PLoS One},
  volume    = {7},
  journal   = {PLoS One},
  number    = {8},
  doi       = {10.1371/journal.pone.0041647},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130041},
  pages     = {e41647},
  year      = {2012},
  abstract  = {Introduction: Oncolytic viruses show promise for treating cancer. However, to assess therapy and potential toxicity, a noninvasive imaging modality is needed. This study aims to determine the in vivo biodistribution, and imaging and timing characteristics of a vaccinia virus, GLV-1h153, encoding the human sodium iodide symporter (hNIS. Methods: GLV-1h153 was modified from GLV-1h68 to encode the hNIS gene. Timing of cellular uptake of radioiodide \(^{131}\)I in human pancreatic carcinoma cells PANC-1 was assessed using radiouptake assays. Viral biodistribution was determined in nude mice bearing PANC-1 xenografts, and infection in tumors confirmed histologically and optically via Green Fluorescent Protein (GFP) and bioluminescence. Timing characteristics of enhanced radiouptake in xenografts were assessed via \(^{124}\)I-positron emission tomography (PET). Detection of systemic administration of virus was investigated with both \(^{124}\)I-PET and 99m-technecium gamma-scintigraphy. Results: GLV-1h153 successfully facilitated time-dependent intracellular uptake of \(^{131}\)I in PANC-1 cells with a maximum uptake at 24 hours postinfection (P < 0.05). In vivo, biodistribution profiles revealed persistence of virus in tumors 5 weeks postinjection at 10\(^9\) plaque-forming unit (PFU)/gm tissue, with the virus mainly cleared from all other major organs. Tumor infection by GLV-1h153 was confirmed via optical imaging and histology. GLV-1h153 facilitated imaging virus replication in tumors via PET even at 8 hours post radiotracer injection, with a mean \% ID/gm of 3.82 \(\pm\) 60.46 (P < 0.05) 2 days after intratumoral administration of virus, confirmed via tissue radiouptake assays. One week post systemic administration, GLV1h153-infected tumors were detected via \(^{124}\)I-PET and 99m-technecium-scintigraphy. Conclusion: GLV-1h153 is a promising oncolytic agent against pancreatic cancer with a promising biosafety profile. GLV-1h153 facilitated time-dependent hNIS-specific radiouptake in pancreatic cancer cells, facilitating detection by PET with both intratumoral and systemic administration. Therefore, GLV-1h153 is a promising candidate for the noninvasive imaging of virotherapy and warrants further study into longterm monitoring of virotherapy and potential radiocombination therapies with this treatment and imaging modality.},
  language  = {en}
}
@article{SteinmannPaeleckeHabermannGeinitzetal.2012,
  author    = {Steinmann, Diana and Paelecke-Habermann, Yvonne and Geinitz, Hans and Aschoff, Raimund and Bayerl, Anja and B{\"o}lling, Tobias and Bosch, Elisabeth and Bruns, Frank and Eichenseder-Seiss, Ute and Gerstein, Johanna and Gharbi, Nadine and Hagg, Juliane and Hipp, Matthias and Kleff, Irmgard and M{\"u}ller, Axel and Sch{\"a}fer, Christof and Schleicher, Ursula and Sehlen, Susanne and Theodorou, Marilena and Wypior, Hans-Joachim and Zehentmayr, Franz and van Oorschot, Birgitt and Vordermark, Dirk},
  title     = {Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases},
  series = {BMC Cancer},
  volume    = {12},
  journal   = {BMC Cancer},
  number    = {283},
  doi       = {10.1186/1471-2407-12-283},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135254},
  year      = {2012},
  abstract  = {Background: Recently published results of quality of life (QoL) studies indicated different outcomes of palliative radiotherapy for brain metastases. This prospective multi-center QoL study of patients with brain metastases was designed to investigate which QoL domains improve or worsen after palliative radiotherapy and which might provide prognostic information. Methods: From 01/2007-01/2009, n=151 patients with previously untreated brain metastases were recruited at 14 centers in Germany and Austria. Most patients (82 \%) received whole-brain radiotherapy. QoL was measured with the EORTC-QLQ-C15-PAL and brain module BN20 before the start of radiotherapy and after 3 months. Results: At 3 months, 88/142 (62 \%) survived. Nine patients were not able to be followed up. 62 patients (70.5 \% of 3-month survivors) completed the second set of questionnaires. Three months after the start of radiotherapy QoL deteriorated significantly in the areas of global QoL, physical function, fatigue, nausea, pain, appetite loss, hair loss, drowsiness, motor dysfunction, communication deficit and weakness of legs. Although the use of corticosteroid at 3 months could be reduced compared to pre-treatment (63 \% vs. 37 \%), the score for headaches remained stable. Initial QoL at the start of treatment was better in those alive than in those deceased at 3 months, significantly for physical function, motor dysfunction and the symptom scales fatigue, pain, appetite loss and weakness of legs. In a multivariate model, lower Karnofsky performance score, higher age and higher pain ratings before radiotherapy were prognostic of 3-month survival. Conclusions: Moderate deterioration in several QoL domains was predominantly observed three months after start of palliative radiotherapy for brain metastases. Future studies will need to address the individual subjective benefit or burden from such treatment. Baseline QoL scores before palliative radiotherapy for brain metastases may contain prognostic information.},
  language  = {en}
}